drugset / Trial / NCT06955858

Clinical Study of rhTPO in Hematopoietic Stem Cell Mobilization for Autologous Transplantation in Acute Leukemia

NCT06955858

NaSingle-groupOpen-labelOther

Summary

Evaluation of the efficacy and safety of recombinant human thrombopoietin (rhTPO) at 300 U/kg/day for hematopoietic stem cell mobilization in autologous transplantation among acute leukemia patients

Timeline

Start
2025-05-30
Primary completion
2026-07-30
Completion
2026-12-30

Drugs

EvaluationDrugModalityDoseRoute
Subject recombinant human thrombopoietin Protein / enzyme biologic 300 iu/kg Subcutaneous
Background G-CSF Unknown 10 ug/kg Subcutaneous